KEYSTEP-004: combination immunotherapy with lenvatinib for advanced HCC

Lorenza Rimassa, MD, IRCCS Humanitas Research Hospital, Milan, Italy, discusses the Phase II KEYSTEP-004 trial (NCT04740307) investigating coformulated quavonlimab and pembrolizumab in combination with lenvatinib for patients with advanced hepatocellular carcinoma (HCC). The trial showed promising results, with high response rates and prolonged survival. However, these findings need to be confirmed in a larger patient population and through Phase III studies. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancer Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.